Glenmark Pharmaceuticals Ltd.
Fundamentals
- Market cap
- ₹60,797 cr
- P/E
- 44.64×
- ROE
- 11.83%
- Debt / equity
- 0.25
- Div yield
- 0.11%
- 52-week range
- 1680.40 — 2474.00
Company snapshot
Glenmark Pharmaceuticals Ltd.
Pharmaceuticals
₹60,763 cr
P/E 44.62×
Latest quarter · Mar 2026
Sales₹3,771 cr
Net profit₹301 cr
Op. margin+20.2%
EPS₹10.68
Strength & growth
Debt / equity0.25×
Current ratio1.56×
Sales CAGR+8.3%
EPS CAGR+6.2%
The timeline — 5 notes on Glenmark Pharmaceuticals Ltd.
June 2026
- 30 Jun 26 · 10:02 PM IST Brief Brief · Large cap
Glenmark gets six FDA observations at Goa plant; supply unaffected
The USFDA inspection ended June 30 with six procedural observations; Glenmark says no impact on commercial products and will respond timely. Observations avoid data integrity and repeat findings.
- 11 Jun 26 · 10:22 AM IST Brief Brief · Large cap
Glenmark lands first new chemical entity in Europe with acne cream
Winlevi, a first-in-class topical acne drug, is now on sale in the Nordics, Central Europe, and Spain. The filing includes zero financial projections.
- 05 Jun 26 · 9:01 AM IST Brief Brief · Earnings · Large cap
Glenmark's transcript adds detail to its margin cut and Envafolimab delay
The Q4 call transcript documents the guidance downgrade to 21-22% EBITDA margin and the push of a key launch to FY28, but adds little new information beyond the concall summary.
- 01 Jun 26 · 9:38 AM IST Brief Brief · Large cap
Glenmark cuts FY27 margin guidance to 21-22%, delays Envafolimab launch
The mid-year guidance cut signals costs and headwinds are deeper than management initially forecast. The oncology launch is now out a year.